Bionomics Limited
Bionomics Limited Fundamental Analysis
Bionomics Limited (BNOX) shows moderate financial fundamentals with a PE ratio of -0.00, profit margin of 565.74%, and ROE of -7.86%. The company generates $-0.5B in annual revenue with weak year-over-year growth of -1.00%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -47.9/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze BNOX's fundamental strength across five key dimensions:
Efficiency Score
WeakBNOX struggles to generate sufficient returns from assets.
Valuation Score
ExcellentBNOX trades at attractive valuation levels.
Growth Score
WeakBNOX faces weak or negative growth trends.
Financial Health Score
ExcellentBNOX maintains a strong and stable balance sheet.
Profitability Score
ModerateBNOX maintains healthy but balanced margins.
Key Financial Metrics
Is BNOX Expensive or Cheap?
P/E Ratio
BNOX trades at -0.00 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, BNOX's PEG of 0.00 indicates potential undervaluation.
Price to Book
The market values Bionomics Limited at 0.00 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -0.03 times EBITDA. This is generally considered low.
How Well Does BNOX Make Money?
Net Profit Margin
For every $100 in sales, Bionomics Limited keeps $565.74 as profit after all expenses.
Operating Margin
Core operations generate 1707.42 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-7.86 in profit for every $100 of shareholder equity.
ROA
Bionomics Limited generates $-10.24 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Bionomics Limited generates limited operating cash flow of $58.10B, signaling weaker underlying cash strength.
Free Cash Flow
Bionomics Limited generates weak or negative free cash flow of $58.10B, restricting financial flexibility.
FCF Per Share
Each share generates $2967.69 in free cash annually.
FCF Yield
BNOX converts 15.09% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-0.00
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.00
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.00
vs 25 benchmark
P/S Ratio
Price to sales ratio
-7.48
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
9.04
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.08
vs 25 benchmark
ROA
Return on assets percentage
-10.24
vs 25 benchmark
ROCE
Return on capital employed
-33.27
vs 25 benchmark
How BNOX Stacks Against Its Sector Peers
| Metric | BNOX Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -0.00 | 29.94 | Better (Cheaper) |
| ROE | -7.86% | 738.00% | Weak |
| Net Margin | 56574.31% | -575975.00% (disorted) | Strong |
| Debt/Equity | 0.00 | 0.44 | Strong (Low Leverage) |
| Current Ratio | 9.04 | 4.49 | Strong Liquidity |
| ROA | -1024.44% | -15756.00% (disorted) | Weak |
BNOX outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Bionomics Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
-100.00%
Industry Style: Defensive, Growth, Innovation
DecliningEPS CAGR
-8362050.44%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
-6904.75%
Industry Style: Defensive, Growth, Innovation
Declining